Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-Oesophageal Junction Adenocarcinoma. Mol. Med. Com. 2023, 3 (02), 89-92. https://doi.org/10.55627/mmc.003.02.0461.